NMPA Notice 2016 No. 61, Annex 3
Technical guideline for human bioequivalence studies of chemical generic drugs with pharmacokinetic endpoints
Current edition
2016 (notice dated 18 March 2016)
Current edition
2016 (notice dated 18 March 2016)
About this standard
General principles for bioequivalence studies of generic chemical drugs that use pharmacokinetic parameters as endpoints: design, subjects, reference product, fed and fasting studies, parameters, statistics and special cases.
Recognition by market
Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts
No market listing is published yet.
Testing requirements that cite it
Open the market page and its pathway pages for the full requirement, protocol and report content
China
- Bioequivalence study design, parameters and acceptance limitsBioequivalence · Not stated
- Waivers of in vivo bioequivalence studies and dissolution similarityBioequivalence · Not stated
Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.